BP CY is a liquid research preparation pairing clenbuterol (a β2-adrenergic agonist) with yohimbine (an α2-adrenergic antagonist). The CYT3 variant adds liothyronine (T3) for comparative thermogenic and lipolytic assays in vitro. This article explains what BP CY is, how its active compounds work, which preparation suits your study design, and how to source it lawfully in South Africa in 2026.
No peer-reviewed adipocyte study published between 2023 and 2026 has co-administered clenbuterol and yohimbine as a defined combination arm. The rationale rests on each compound's independently characterised receptor pharmacology. For South African laboratory coordinators, the 2026 sourcing picture is constrained: yohimbine HCl remains treated as a scheduled active under the Medicines and Related Substances Act, and no BP CY-specific Certificate of Analysis (CoA), mg/mL specification or solvent declaration is publicly indexed by local vendors.
Key Takeaways
- BP CY pairs clenbuterol (β2-agonist) and yohimbine (α2-antagonist) for in vitro adrenergic research; CYT3 adds T3 for thyroid-axis studies
- No published adipocyte study has characterised this specific combination; the rationale derives from independent receptor pharmacology
- Both actives are scheduled substances in South Africa; institutional REC and SAHPRA compliance is mandatory before procurement
- Quality assurance requires ≥98% HPLC purity per active, declared solvent composition, and cold-chain handling
- BP CY isolates adrenergic thermogenesis; CYT3 enables multi-pathway studies combining GPCR and nuclear receptor signalling
What Is BP CY? Compound Overview
BP CY is a dual-compound research preparation containing clenbuterol hydrochloride (a β2-adrenergic agonist) and yohimbine hydrochloride (a selective α2-adrenergic antagonist). It is supplied as a liquid for in vitro investigation of adrenergic-mediated thermogenesis and lipolysis. The CYT3 variant adds liothyronine (T3) for parallel thyroid-axis comparison arms.
Public vendor documentation from 2024–2026 does not disclose BP CY's exact mg/mL specification, fill volume, or solvent system. Manufacturers typically reserve this information for institutional procurement agreements. Any laboratory adopting the preparation should request a current CoA and composition declaration in writing before assay inclusion. Internationally, comparable grey-market liquid blends of this class are formatted in the 1–5 mg/mL range per active in hydroalcoholic or polyethylene glycol (PEG)-based vehicles, though this is a niche pattern rather than a BP CY-specific specification.
The pharmacological rationale for pairing the two actives derives from their independently characterised receptor profiles, not from a co-treatment adipocyte study. Yohimbine is catalogued as a centrally acting α2-antagonist. Clenbuterol's β2-agonist activity forms the basis for its use as a lipolytic probe. Researchers comparing standalone material to the blend can cross-reference the BP Clenbuterol 40 entry within the broader clenbuterol research preparations catalogue.
Active Compounds: Mechanisms at a Glance
Each active in BP CY and CYT3 targets a distinct receptor population. The compounds are not redundant: β2-agonism drives the lipolytic signal, α2-antagonism removes a Gi-mediated brake on that same signal, and T3 modulates the transcriptional substrate the assay reads against.
Clenbuterol, β2-adrenergic agonism
Clenbuterol is a long-acting β2-adrenergic receptor agonist originally developed for bronchodilation. In metabolic assays, it is a Gs-coupled probe for cyclic adenosine monophosphate (cAMP)–protein kinase A (PKA)–hormone-sensitive lipase (HSL) signalling. Receptor engagement activates adenylyl cyclase and elevates intracellular cAMP. This triggers PKA-mediated phosphorylation of HSL and perilipin, releasing free fatty acids from triglyceride stores. In the BP CY context, clenbuterol provides the positive lipolytic drive against which yohimbine's disinhibitory effect can be quantified.
Yohimbine, α2-adrenergic antagonism
Yohimbine is a selective α2-adrenergic receptor antagonist catalogued as a centrally acting agent and prescription-only active internationally. Blocking α2-adrenergic receptors (α2-ARs) removes Gi-mediated inhibition of adenylyl cyclase. Any concurrent Gs input, here, clenbuterol at β2, produces a larger net cAMP rise than either compound alone would predict from its isolated dose-response. α2-ARs are densely expressed in human gluteal and abdominal subcutaneous adipose tissue, which is why yohimbine is a standard pharmacological tool for probing regional adipocyte sensitivity. No peer-reviewed adipocyte study published between 2023 and 2026 has formally co-treated with clenbuterol and yohimbine. The synergy is inferred from independent receptor pharmacology rather than a defined combination paper.
T3 (CYT3 only), nuclear thyroid receptor activation
Liothyronine (T3) acts via nuclear thyroid hormone receptors (TRα, TRβ). It upregulates transcription of uncoupling protein 1 (UCP1) and other genes that raise basal metabolic rate and mitochondrial uncoupling capacity. In the CYT3 variant, T3 is included so a thyroid-axis arm can run in parallel with the pure adrenergic arm, isolating transcriptional from GPCR contributions within the same assay window.
| Compound | Receptor Target | Primary Effect in Assay |
|---|---|---|
| Clenbuterol | β2-AR (Gs) | ↑ cAMP, PKA, HSL phosphorylation → lipolysis |
| Yohimbine | α2-AR (antagonist) | Removes Gi inhibition of adenylyl cyclase → amplifies cAMP |
| T3 (CYT3) | Nuclear TRα/TRβ | ↑ UCP1 transcription, ↑ metabolic rate |
Researchers benchmarking the blend against a single-active control can compare specifications to the BP Clenbuterol 40 listing within the wider clenbuterol research preparations range. Any human efficacy figures from pre-2023 literature should be treated as potentially stale for clinical extrapolation. The receptor-level mechanisms cited above are stable, but quantitative translation to 2026 in vivo expectations is not.
Why Combine β2 Agonism with α2 Antagonism?
The clenbuterol–yohimbine pairing exploits a push-pull at the adenylyl cyclase node. Clenbuterol drives Gs-coupled cAMP generation through β2-AR, while yohimbine blocks α2-AR-mediated Gi inhibition that would otherwise clamp the same cyclase pool. The net effect in adipocyte preparations is a higher, less-dampened cAMP plateau and, downstream, more sustained HSL phosphorylation than β2 stimulation alone would produce.
This matters most in adipose depots where α2-AR density rivals or exceeds β-AR density. Femorogluteal and subcutaneous abdominal adipose tissue in human primary adipocytes show this pattern. In those cells, a β-agonist titration curve flattens early without α2 blockade. Co-application is a textbook way to expose that ceiling and quantify the α2-imposed brake within a single assay window.
No peer-reviewed paper published between 2023 and 2026 has run clenbuterol and yohimbine as a defined co-treatment arm in 3T3-L1 or primary adipocyte models. The rationale rests on independent β2 and α2 pharmacology rather than a combination study. Teams running standalone β2 controls in parallel typically reference single-active material such as BP Clenbuterol 40 from the broader clenbuterol research preparations range to isolate the α2-antagonism contribution.
BP CY vs CYT3: Which Preparation for Your Study?
BP CY contains clenbuterol and yohimbine only, making it appropriate for studies isolating adrenergic thermogenesis without thyroid-axis confounding. CYT3 adds liothyronine (T3) to the same two actives, making it appropriate for studies examining multi-pathway thermogenic interaction where nuclear thyroid signalling is part of the model. The choice hinges on whether the assay needs to hold TRα/TRβ activity constant or deliberately vary it.
T3 binds nuclear thyroid hormone receptors (TRα/TRβ) and modulates transcription of UCP and lipolytic genes on a timescale of hours. Clenbuterol (β2-AR) and yohimbine (α2-AR) act at membrane GPCRs with second-messenger responses on a timescale of minutes. A CYT3 arm therefore overlays a slow transcriptional axis on a fast cAMP/HSL axis, a combined thermogenic environment frequently used in obesity and metabolic-syndrome cell models.
| Preparation | Components | Recommended Assay Context | Variable Isolated |
|---|---|---|---|
| BP CY | Clenbuterol + yohimbine | Acute lipolysis, cAMP/HSL phosphorylation, β2/α2 receptor cross-talk in 3T3-L1 or primary adipocytes | Adrenergic-only thermogenic drive (membrane GPCR layer) |
| CYT3 | Clenbuterol + yohimbine + T3 | Longer-window (≥24 h) assays modelling adrenergic-thyroid interaction; mitochondrial uncoupling readouts | Three-pathway synergy across GPCR and nuclear receptor signalling |
Teams running a clenbuterol-only control alongside BP CY typically draw from single-active material such as BP Clenbuterol 40 within the wider clenbuterol research preparations range, then add the BP CY or CYT3 arm to quantify what each additional receptor layer contributes. No peer-reviewed paper published between 2023 and 2026 has characterised either BP CY or CYT3 as a defined co-treatment arm in adipocyte models.
Research Applications in 2026
BP CY and CYT3 see use in four South African in vitro contexts in 2026: acute lipolysis assays, comparative thermogenesis readouts, adrenergic receptor cross-talk experiments, and metabolic-disease cell models. All four are bench applications. Neither preparation is intended for animal dosing or human administration outside a protocol cleared by an institutional ethics committee and, where applicable, SAHPRA Section 21 authorisation.
3T3-L1 and primary human adipocyte lipolysis assays use BP CY to quantify glycerol and non-esterified fatty acid release when β2-agonism runs with simultaneous α2-blockade. This isolates the autocrine α2-brake that suppresses cAMP accumulation under clenbuterol alone. Comparative thermogenesis studies pair the blend with Seahorse-style oxygen consumption measurements or UCP1 transcript/protein quantification. CYT3 is reserved for ≥24 h windows where T3-driven transcriptional uncoupling overlays the adrenergic signal. Adrenergic receptor cross-talk work uses BP CY to probe β2/α2 GPCR convergence on PKA, HSL phosphorylation, and perilipin dynamics. Obesity and insulin-resistance models place these readouts in a disease context, typically against lipid-loaded or tumour necrosis factor-alpha (TNF-α)-challenged adipocytes.
No peer-reviewed paper published between 2023 and 2026 has run BP CY or CYT3 as a defined co-treatment arm in adipocyte models. Each laboratory characterises the combination de novo against its own controls.
Local interest in this adrenergic axis has grown alongside the 2024–2026 surge in glucagon-like peptide-1 (GLP-1) receptor agonist research. The BP Clenbuterol 40 single-active and the broader clenbuterol research preparations range are commonly used as the β2-only baseline against which BP CY's added α2-antagonism is measured. The adrenergic mechanism here is mechanistically distinct from, and complementary to, the incretin pathway probed by tirzepatide, semaglutide, and retatrutide preparations.
Regulatory Status in South Africa (2026)
BP CY cannot be lawfully procured for human use in South Africa. It is supplied strictly as an in vitro research preparation. Both actives sit inside the scheduled-medicines framework of the Medicines and Related Substances Act 101 of 1965, administered by SAHPRA (sahpra.org.za).
Clenbuterol is a Schedule 4 substance under Act 101 of 1965, meaning prescription-only status for any human-directed supply. Yohimbine hydrochloride continues to be treated as a scheduled active in South African practice, aligning with Schedule 4 in the historical Gazette tables for erectile dysfunction indications. No SAHPRA Gazette notice published between 2024 and 2026 has descheduled or down-scheduled it. Internationally it remains catalogued as a prescription-class α2-antagonist rather than a nutraceutical.
In vitro research use vs human-use supply
Research chemicals supplied for laboratory use occupy a regulatory space distinct from medicines registered for human administration. BP CY is not approved for human consumption and is supplied solely for in vitro work against cultured cells or cell-free systems. Procurement for institutional research typically routes through a Section 21 authorisation or an exemption pathway where applicable, plus the institution's own scheduled-substances procurement controls. Researchers concerned about compliance should confirm their institution's standard operating procedures before placing an order.
Ethics and institutional approval
Before placing an order, confirm Research Ethics Committee (REC) approval at your institution. Your institution's REC must be registered with the National Health Research Ethics Committee. Confirm alignment with SAHPRA scheduling. Researchers comparing the blend against single-active baselines such as BP Clenbuterol 40, or pulling from the wider clenbuterol research preparations range, should document each scheduled compound on the same protocol amendment.
Sourcing BP CY in South Africa: What to Look For
A quality-assured BP CY supply is one where each scheduled active is independently characterised by high-performance liquid chromatography (HPLC), the solvent system is declared in writing, and shipping preserves compound integrity from dispatch to receipt. Research-grade in this context means ≥98% HPLC purity per active, with chromatograms and a specified contaminant profile on the CoA. That standard is not equivalent to pharmaceutical-grade material released for human administration. Pharmaceutical-grade material requires SAHPRA registration and Good Manufacturing Practice (GMP) manufacturing dossiers. Neither BP CY nor any other research preparation holds these credentials.
Research Preparation Quality Checklist, Five Points to Verify Before Ordering
- CoA with HPLC purity data, separate purity figures for clenbuterol HCl and yohimbine HCl, each ≥98%, with chromatograms dated within the current production batch.
- Stated concentration and solvent composition, mg/mL per active, total fill volume, and full excipient/solvent declaration (e.g., hydroalcoholic vehicle, PEG content) in writing before dispatch.
- Cold-chain or appropriate storage in transit, amber glass, temperature-controlled handling where the CoA specifies it, and documented transit times.
- Tracked shipping with chain-of-custody, courier waybill, tamper-evident seals, and a signed handover at the institutional receiving point.
- Verifiable supplier identity and secure checkout, registered South African entity, HTTPS payment processing, and a contactable technical representative.
JCSG.org supplies BP CY against these five markers. Researchers cross-checking the blend against single-active baselines can review BP Clenbuterol 40 or the full clenbuterol research preparations catalogue for comparative CoA formats.
Related Research Preparations on JCSG.org SA
Researchers building multi-arm metabolic studies around BP CY typically pair it with adjacent thermogenic, lipolytic, or incretin-pathway preparations from the same catalogue. Each compound below targets a distinct receptor or enzymatic node, making them useful comparators rather than substitutes.
BP Clenbuterol 40 supplies clenbuterol HCl as a single active, isolating β2-adrenergic signalling from the α2-antagonism contributed by yohimbine in the BP CY blend. The broader clenbuterol research preparations category lists every clenbuterol-containing format JCSG.org SA stocks, including the CYT3 (plus T3) variant for thyroid-axis co-treatment arms.
For lipolytic comparators acting outside the adrenergic system, AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone, studied for lipolytic activity independent of β-adrenergic receptors, a mechanistically distinct counterpoint to clenbuterol in adipocyte assays. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue that drives endogenous growth hormone pulsatility and has documented effects on visceral adipose tissue. The incretin-axis preparations (Tirzepatide, Semaglutide, Retatrutide, and the Tirsema combination format) extend comparative work into GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor pharmacology relevant to integrated metabolic studies.
Frequently Asked Questions
What is the difference between BP CY and CYT3?
BP CY contains clenbuterol HCl plus yohimbine HCl, pairing β2-adrenergic agonism with α2-adrenergic antagonism. CYT3 adds liothyronine (T3) as a third active, enabling thyroid-axis co-treatment arms within the same vehicle. Researchers running comparative metabolic assays typically use BP CY for adrenergic-only work and CYT3 where thyroid hormone signalling is a study variable.
Is clenbuterol legal in South Africa for research use?
Clenbuterol is not registered for human use in South Africa and is treated as a scheduled substance under the Medicines and Related Substances Act 101 of 1965. Yohimbine is similarly handled as a scheduled active in human-use contexts. Institutional procurement for in vitro research must follow SAHPRA controls and internal standard operating procedures (SOPs). No NHREC-specific procurement guidance for research chemicals has been issued between 2023 and 2026.
What cell lines are most commonly used with this preparation?
3T3-L1 murine adipocytes and primary human subcutaneous adipocytes are the standard models for β2/α2-adrenergic lipolysis work. No peer-reviewed study published between 2023 and 2026 has used the specific clenbuterol plus yohimbine combination as a defined co-treatment arm. Researchers comparing single-agent kinetics may reference BP Clenbuterol 40 as a monotherapy control within the broader clenbuterol research preparations range.
How should BP CY be stored?
Store at 2–8 °C for short-term working stocks and at −20 °C for long-term aliquots. Protect from light and moisture. Public documentation from 2024–2026 does not disclose BP CY's specific solvent system. Request the supplier CoA before finalising storage SOPs.
Can BP CY be used in animal studies?
Animal use requires Animal Research Ethics Committee (AREC) approval at the host institution in addition to standard in vitro biosafety clearance. It falls outside the scope of in vitro-only procurement justifications.
Next Steps
Confirm REC registration and SAHPRA compliance at your institution before proceeding. Request a current Certificate of Analysis and solvent composition declaration from your supplier. Review the BP Clenbuterol 40 single-active entry to establish your β2-only control arm, then add BP CY or CYT3 to quantify the contribution of α2-antagonism or thyroid-axis signalling to your assay readout.
